Monocarboxylate transporter 1 blockade with AZD3965 inhibits lipid biosynthesis and increases tumour immune cell infiltration

Published on Jan 15, 2020in British Journal of Cancer5.416
· DOI :10.1038/s41416-019-0717-x
Mounia Beloueche-Babari12
Estimated H-index: 12
(The Royal Marsden NHS Foundation Trust),
Teresa Casals Galobart2
Estimated H-index: 2
(The Royal Marsden NHS Foundation Trust)
+ 5 AuthorsMartin O. Leach70
Estimated H-index: 70
(The Royal Marsden NHS Foundation Trust)
Monocarboxylate transporter 1 (MCT1) is a regulator of cell metabolism and a therapeutic target for cancer treatment. Understanding the changes in tumour function accompanying MCT1 inhibition will better characterise the anti-tumour effects of MCT1 inhibitors, potentially enabling the identification of pharmacodynamic biomarkers for the clinical development of these agents. We assessed the impact of the MCT1 inhibitor AZD3965 on tumour metabolism and immune cell infiltration as key determinants of tumour biological function in the MCT1-dependent Raji B cell lymphoma model. Treatment of Raji xenograft-bearing severe combined immunodeficiency mice with AZD3965 led to inhibition of tumour growth paralleled with a decrease in tumour choline, as detected by non-invasive in vivo proton nuclear magnetic resonance spectroscopy. This effect was attributed to inhibition of phosphocholine de novo synthesis following decreased choline kinase α protein and messenger RNA expression that correlated with the AZD3965-induced build-up in intracellular lactate. These changes were concomitant with increased tumour immune cell infiltration involving dendritic and natural killer cells. Our data provide new insights into the metabolic and cellular changes that occur in the tumour microenvironment following MCT1 blockade, which may contribute to the anti-tumour activity of AZD3965 and could have potential as pharmacodynamic biomarkers of MCT1 inhibition.
  • References (39)
  • Citations (0)
📖 Papers frequently viewed together
20 Authors (Jiyun Lee, ..., W.K. Kang)
15 Citations
18 Citations
35 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
#1Hugo GonzalezH-Index: 2
Last. Zena WerbH-Index: 149
view all 3 authors...
Author(s): Gonzalez, Hugo; Hagerling, Catharina; Werb, Zena | Abstract: The presence of inflammatory immune cells in human tumors raises a fundamental question in oncology: How do cancer cells avoid the destruction by immune attack? In principle, tumor development can be controlled by cytotoxic innate and adaptive immune cells; however, as the tumor develops from neoplastic tissue to clinically detectable tumors, cancer cells evolve different mechanisms that mimic peripheral immune tolerance in ...
17 CitationsSource
Hyperpolarization of 13C-labeled substrates can increase their 13C NMR signal by more than 10 000-fold, which has allowed magnetic resonance imaging (MRI) of metabolic reactions in vivo. This has already provided a unique insight into the dysregulated metabolic pathways and microenvironment of tumors. Perhaps the best known of the cancer-associated metabolic aberrations is the Warburg effect, which has been imaged in patients using hyperpolarized [1-13C]pyruvate. In clinical oncology there is a ...
4 CitationsSource
#1Roberta Zappasodi (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 13
#2Taha Merghoub (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 45
Last. Jedd D. WolchokH-Index: 105
view all 3 authors...
Checkpoint blockade has formally demonstrated that reactivating anti-tumor immune responses can regress tumors. However, this only occurs in a fraction of patients. Incorporating these therapies in more powerful combinations is thus a logical next step. Here, we review functional roles of immune checkpoints and molecular determinants of checkpoint-blockade clinical activity. Limited-size T cell-infiltrated tumors, differing substantially from "self," generally respond to checkpoint blockade. The...
77 CitationsSource
#1Alexandre Morrot (FIOCRUZ: Oswaldo Cruz Foundation)H-Index: 23
#2Leonardo Marques da Fonseca (UFRJ: Federal University of Rio de Janeiro)H-Index: 6
Last. Leonardo Freire-de-Lima (UFRJ: Federal University of Rio de Janeiro)H-Index: 14
view all 10 authors...
The tumor microenvironment (TME) is composed by cellular as well as non-cellular components. Examples include: (i) bone marrow-derived inflammatory cells, (ii) fibroblasts, (iii) blood vessels, (iv) immune cells and (v) extracellular matrix (ECM) components. In most cases, this combination of components may result in an inhospitable environment, in which a significant retrenchment in nutrients and oxygen considerably disturbs cell metabolism. Cancer cells are characterized by an enhanced uptake ...
10 CitationsSource
#1Costas A. Lyssiotis (UM: University of Michigan)H-Index: 32
#2Alec C. Kimmelman (NYU: New York University)H-Index: 48
Tumors are dynamic pseudoorgans that contain numerous cell types interacting to create a unique physiology. Within this network, the malignant cells encounter many challenges and rewire their metabolic properties accordingly. Such changes can be experienced and executed autonomously or through interaction with other cells in the tumor. The focus of this review is on the remodeling of the tumor microenvironment that leads to pathophysiologic interactions that are influenced and shaped by metaboli...
98 CitationsSource
#1Mounia Beloueche-Babari (The Royal Marsden NHS Foundation Trust)H-Index: 12
#2Slawomir Wantuch (The Royal Marsden NHS Foundation Trust)H-Index: 2
Last. Martin O. Leach (The Royal Marsden NHS Foundation Trust)H-Index: 70
view all 10 authors...
Monocarboxylate transporters (MCT) modulate tumor cell metabolism and offer promising therapeutic targets for cancer treatment. Understanding the impact of MCT blockade on tumor cell metabolism may help develop combination strategies or identify pharmacodynamic biomarkers to support the clinical development of MCT inhibitors now in clinical trials. In this study, we assessed the impact of the MCT1 inhibitor AZD3965 on cancer cell metabolism in vitro and in vivo . Exposing human lymphoma and colo...
11 CitationsSource
#1Hong XieH-Index: 4
#2M. Celeste Simon (UPenn: University of Pennsylvania)H-Index: 84
Abstract Hypoxia and dysregulated metabolism are defining features of solid tumors. How cancer cells adapt to low O2 has been illuminated by numerous studies, with "reprogrammed" metabolism being one of the most important mechanisms. This metabolic reprogramming not only promotes cancer cell plasticity, but also provides novel insights for treatment strategies. As the most studied O2 "sensor", hypoxia-inducible factor (HIF) is regarded as an important regulator of hypoxia-induced transcriptional...
40 CitationsSource
#1Chloe J. Pyle (NIH: National Institutes of Health)H-Index: 2
#2Faith I. Uwadiae (NIH: National Institutes of Health)H-Index: 2
Last. James A. Harker (NIH: National Institutes of Health)H-Index: 19
view all 4 authors...
Interleukin-6 is a pleiotropic, pro-inflammatory cytokine that can promote both innate and adaptive immune responses. In humans with respiratory virus infections, such as Respiratory Syncytial Virus (RSV), elevated concentrations of IL-6 are associated with more severe disease. In contrast the polymorphisms in the Il6 promoter which favour lower IL-6 production are associated with increased risk of both RSV and Rhinovirus infections. To determine the precise contribution of IL-6 to protection an...
19 CitationsSource
#1N.J. CurtisH-Index: 4
#2Lorraine MooneyH-Index: 4
Last. Susan E. CritchlowH-Index: 12
view all 15 authors...
// Nicola J. Curtis 1 , Lorraine Mooney 1 , Lorna Hopcroft 2 , Filippos Michopoulos 1 , Nichola Whalley 2 , Haihong Zhong 3 , Clare Murray 4,6 , Armelle Logie 1 , Mitchell Revill 1 , Kate F. Byth 5 , Amanda D. Benjamin 4 , Mike A. Firth 1 , Stephen Green 1 , Paul D. Smith 2 and Susan E. Critchlow 2 1 iMED Oncology, AstraZeneca, Alderley Park, Cheshire, UK 2 iMED Oncology, AstraZeneca, Cambridge, UK 3 MedImmune, One MedImmune Way, Gaithersburg, MD, USA 4 iMED DSM, AstraZeneca, Cambridge, UK 5 iME...
9 CitationsSource
#1Gabriela Andrejeva (VUMC: Vanderbilt University Medical Center)H-Index: 5
#2Jeffrey C. Rathmell (VUMC: Vanderbilt University Medical Center)H-Index: 59
It has been appreciated for nearly 100 years that cancer cells are metabolically distinct from resting tissues. More recently understood is that this metabolic phenotype is not unique to cancer cells but instead reflects characteristics of proliferating cells. Similar metabolic transitions also occur in the immune system as cells transition from resting state to stimulated effectors. A key finding in immune metabolism is that the metabolic programs of different cell subsets are distinctly associ...
33 CitationsSource
Cited By0